fda compounding semaglutide enforcement november 2025 news Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" FDA and Novo Nordisk Warned
Description
Importantly, GLP-1 receptor agonists are not indicated for type 1 diabetes or diabetic ketoacidosis, and should not be co-prescribed with DPP-4 inhibitors (such as sitagliptin or linagliptin)
Manage Setbacks Setbacks are part of the weight loss journey, no matter who you are
Quality Control and Testing Procedures: What quality control testing is performed on each medication batch
Zepbound, on the other hand, contains tirzepatide, which targets both GLP-1 and GIP receptors, helping to suppress appetite and enhance satiety
Its small size and endogenous origin make it a common target in mechanistic peptide research
GLP-1 receptor agonists (including semaglutide and tirzepatide) are prescription-only medicines
